Cargando…
Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?
BACKGROUND: Agomelatine, the first melatonergic antidepressant, has been postulated to enhance the dopaminergic activity at the central nervous system by 5-hydroxytryptamine receptor type 2C (5-HT2C) antagonism, yet the impact of melatonergic agonism on this pathway is unclear. Previous studies empl...
Autores principales: | Fornaro, Michele, Bandini, Fabio, Cestari, Luca, Cordano, Christian, Ogliastro, Carla, Albano, Claudio, De Berardis, Domenico, Martino, Matteo, Escelsior, Andrea, Rocchi, Giulio, Fornaro, Pantaleo, De Pasquale, Concetta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038423/ https://www.ncbi.nlm.nih.gov/pubmed/24899809 http://dx.doi.org/10.2147/NDT.S63459 |
Ejemplares similares
-
Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
por: Fornaro, Michele, et al.
Publicado: (2013) -
Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
por: Martino, Matteo, et al.
Publicado: (2012) -
A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
por: Fornaro, Michele, et al.
Publicado: (2010) -
The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice
por: De Berardis, Domenico, et al.
Publicado: (2013) -
An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects
por: Fornaro, Michele, et al.
Publicado: (2011)